# Ne oldu?

Baxter International Inc. has voluntarily recalled two lots of 0.9% Sodium Chloride Injection due to the potential presence of particulate matter identified as fiberglass. The recall was announced on August 25, 2026. Intravenous administration of the affected product may lead to serious adverse health consequences, including vessel blockage, clotting, pulmonary embolism, permanent organ damage, or death. As of the recall date, Baxter has not received any reports of adverse events related to this issue.

# Ayrıntılar

The affected product is 0.9% Sodium Chloride Injection, USP, 500 mL VIAFLEX Plastic Container, supplied in cases of 24 units. The recall involves only two specific lots; other lots of the product are not affected. The fiberglass particulate matter was identified during routine quality testing. Baxter is notifying healthcare facilities and distributors directly and arranging for return of the recalled inventory.

# Neden önemli?

This recall is classified as high risk because intravenous administration of contaminated fluid can introduce foreign particles directly into the bloodstream. Particulate matter can cause blockage and clotting in blood vessels, which can cut off blood flow to vital organs, lead to a life-threatening blood clot in the lungs (pulmonary embolism), and cause permanent organ damage or death. Patients receiving infusion therapy with the affected lots are at risk of serious complications.

# Arka plan

Baxter International Inc. (NYSE: BAX) is a global leader in medical products, including intravenous fluids and therapies. The company routinely conducts quality testing and initiates recalls when safety concerns are identified. This voluntary recall underscores the importance of rigorous quality control in the manufacturing of intravenous fluids, which are used in a wide range of clinical settings from routine hydration to emergency care and hemodialysis priming.

# Sırada ne var?

Healthcare providers and facilities are urged to check their inventory for the affected lots and immediately quarantine any identified product. Baxter is coordinating with distributors to facilitate the return process. Patients currently receiving intravenous therapy should consult their healthcare team if they have concerns about the specific fluid being administered. No adverse events have been reported to date, but the company and FDA continue to monitor for any emerging reports.